title: Implications of group III and IV muscle afferents for high-intensity endurance exercise performance in humans.
abstract: We investigated the influence of group III/IV muscle afferents on peripheral fatigue, central motor drive (CMD) and endurance capacity during high-intensity leg-cycling. In a double-blind, placebo-controlled design, seven males performed constant-load cycling exercise (318 ± 9 W; 80% of peak power output (W(peak))) to exhaustion under placebo conditions and with lumbar intrathecal fentanyl impairing spinal μ-opioid receptor-sensitive group III/IV muscle afferents. Peripheral fatigue was assessed via changes in pre- vs. post-exercise quadriceps force in response to supramaximal magnetic femoral nerve stimulation (ΔQ(tw,pot)). CMD was estimated via quadriceps electromyogram. To rule out a direct central effect of fentanyl, we documented unchanged resting cardioventilatory responses. Compared to placebo, significant hypoventilation during the fentanyl trial was indicated by the 9% lower V(E)/V(CO(2)), causing a 5 mmHg increase in end-tidal P(CO(2)) and a 3% lower haemoglobin saturation. Arterial pressure and heart rate averaged 8 and 10% lower, respectively, during the fentanyl trial and these differences progressively diminished towards end-exercise. Although initially similar, the percent change in CMD was 9 ± 3% higher at end-exercise with fentanyl vs. placebo (P < 0.05). Time to exhaustion was shorter (6.8 ± 0.3 min vs. 8.7 ± 0.3 min) and end-exercise ΔQ(tw,pot) was about one-third greater (-44 ± 2% vs. -34 ± 2%) following fentanyl vs. placebo. The rate of peripheral fatigue development was 67 ± 10% greater during the fentanyl trial (P < 0.01). Our findings suggest that feedback from group III/IV muscle afferents limits CMD but also minimizes locomotor muscle fatigue development by stimulating adequate ventilatory and circulatory responses to exercise. In the face of blocked group III/IV muscle afferents, CMD is less inhibited but O(2) transport compromised and locomotor muscle fatigability is exacerbated with a combined net effect of a reduced endurance performance.
authors: University of Utah, Department of Internal Medicine, Salt Lake City, UT, USA. markus.amann@hsc.utah.edu
authors: Markus
authors: M
authors: Amann
authors: Gregory M
authors: GM
authors: Blain
authors: Lester T
authors: LT
authors: Proctor
authors: Joshua J
authors: JJ
authors: Sebranek
authors: David F
authors: DF
authors: Pegelow
authors: Jerome A
authors: JA
authors: Dempsey
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000494:pharmacology; D004576:Electromyography; D015444:Exercise / Q000502:physiology*; D005283:Fentanyl / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D055909:Magnetic Field Therapy; D008297:Male; D018763:Muscle Fatigue / Q000502:physiology*; D018485:Muscle Fibers, Skeletal / Q000502:physiology*; D010807:Physical Endurance; D012123:Pulmonary Ventilation / Q000187:drug effects; D052097:Quadriceps Muscle / Q000502:physiology*; D055815:Young Adult
chemical_list: D000701:Analgesics, Opioid; D005283:Fentanyl